GlaxoSmithKline licenses cancer antigen portfolio

By Elaine Rigoli

Tampa, Fla., June 5 - GlaxoSmithKline plc and the international Ludwig Institute for Cancer Research announced it has entered into an agreement whereby GlaxoSmithKline has licensed a substantial portfolio of tumor-specific antigens from the Ludwig Institute.

Under the agreement, GlaxoSmithKline has licensed a significant number of cancer antigens expressed in a large variety of cancers, including non-small cell lung cancer, melanoma, breast cancer, head and neck cancer, bladder cancer and liver cancer.

The financial details of the agreement were not disclosed.

The Ludwig Institute for Cancer Research is a New York-based academic institute dedicated to understanding and controlling cancer.

GlaxoSmithKline, based in London, is a global research-based pharmaceutical and health care company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.